



**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 63502

**Manuscript Type:** MINIREVIEWS

**Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy**

Prevention of hepatitis B reactivation

Chih-An Shih, Wen-Chi Chen

**Match Overview**

1	<b>Crossref</b> 80 words Sirina Ekpanyapong, K. Rajender Reddy. "Hepatitis B Virus Reactivation", <i>Clinics in Liver Disease</i> , 2020	2%
2	<b>Crossref</b> 71 words Rohit Loomba, T. Jake Liang. "Hepatitis B Reactivation Associated With Immune Suppressive and Biological M ..."	2%
3	<b>Internet</b> 64 words crawled on 21-Aug-2020 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	2%
4	<b>Internet</b> 56 words crawled on 03-Dec-2020 <a href="http://academic.oup.com">academic.oup.com</a>	2%
5	<b>Internet</b> 42 words crawled on 10-Oct-2019 <a href="http://journals.plos.org">journals.plos.org</a>	1%
6	<b>Crossref</b> 40 words Hwang, Jessica P., and Anna S.-F. Lok. "Management of patients with hepatitis B who require immunosuppres ..."	1%
7	<b>Internet</b> 27 words	10%



ALL

IMAGES

VIDEOS

443,000 Results

Any time ▾

## Prevention of hepatitis B virus reactivation in patients ...

<https://pubmed.ncbi.nlm.nih.gov/22686858>

Prevention of **hepatitis B virus reactivation** in patients receiving immunosuppressive therapy or chemotherapy. With the increasing use of potent immunosuppressive therapy, reactivation of hepatitis B virus (HBV) in endemic regions is becoming a clinical problem requiring special attention. A recent annual nationwide survey clarified that HBV reactivation related to immunosuppressive therapy has been ...

Cited by: 96

Author: Makoto Oketani, Akio Ido, Hirofumi Uto, ...

Publish Year: 2012

## Characteristics, Prevention, and Management of Hepatitis B ...

<https://pubmed.ncbi.nlm.nih.gov/29156044>

There is mounting evidence that HBV reactivation can be prevented and managed if patients are screened to determine their risk for HBV reactivation and are treated prophylactically before therapy with immunosuppressive agents or cytotoxic chemotherapy is initiated.

Cited by: 6

Author: Jonggi Choi, Young-Suk Lim

Publish Year: 2017

## [Immunosuppressive therapy or chemotherapy-induced ...

<https://pubmed.ncbi.nlm.nih.gov/21368477>

This is because de novo hepatitis B, which occurs in HBV-resolved patients with a recurrence of HBV hepatitis, have a high risk of fulminant hepatitis with an extremely poor prognosis. In this regard, prevention a guideline for IS/ CT-induced HBV-reactivation was established in Japan.

Author: Kazuya Sato

Publish Year: 2011

## Antiviral prophylaxis during chemotherapy or ...

<https://pubmed.ncbi.nlm.nih.gov/29845351>

Background: Until recently, the role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation during immunosuppressive therapy or chemotherapy in patients with resolved HBV infection was unclear. The aim of the study reported here was to compare the efficacy of antiviral prophylaxis versus that of non-prophylaxis in resolved HBV-infected patients undergoing chemotherapy or ...

Cited by: 2

Author: Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu...

Publish Year: 2018



ALL

IMAGES

VIDEOS

Add the Give with Bing extension &gt;

414,000 Results

Any time ▾

## Prevention of hepatitis B virus reactivation in patients ...

<https://pubmed.ncbi.nlm.nih.gov/22686858>

Prevention of **hepatitis B virus reactivation** in patients receiving immunosuppressive therapy or chemotherapy. With the increasing use of potent immunosuppressive therapy, reactivation of hepatitis B virus (HBV) in endemic regions is becoming a clinical problem requiring special attention. A recent annual nationwide survey clarified that HBV reactivation related to ...

**Cited by:** 95**Author:** Makoto Oketani, Akio Ido, Hirofumi Ut...**Publish Year:** 2012

## Prevention of Hepatitis B reactivation in the setting of ...

<https://pubmed.ncbi.nlm.nih.gov/27291888>

Individuals with chronic **hepatitis B** (CHB) and previously infected but serologically cleared HBV infection are both susceptible to HBV **reactivation**. HBV **reactivation** in the setting of immunosuppression is a potentially life threatening condition leading ...

**Cited by:** 75**Author:** Venessa Pattullo**Publish Year:** 2016

## Hepatitis B reactivation in the setting of chemotherapy ...

## Hepatitis B virus

Dna Viru



Hepatitis B virus, is a partially double-stranded DNA virus, a species of the genus Orthohepadnavirus and a member of the Hepadnaviridae family of viruses. This virus causes the disease hepatitis B.

Wikipedia

**Scientific name:** Hepatitis B virus**Family:** Hepadnaviridae**Genus:** Orthohepadnavirus**Domain:** Virus**Class:** Revtraviricetes**Biological rank:** Species

激活 Windows

转到“设置”以激活 Windows。

431,000 Results Any time ▾

### Prevention of hepatitis B virus reactivation in patients ...

<https://pubmed.ncbi.nlm.nih.gov/22686858>

Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. With the increasing use of potent immunosuppressive therapy, reactivation of hepatitis ...

Cited by: 95 Author: Makoto Oketani, Akio Ido, Hirofumi Uto, Hir...  
Publish Year: 2012

### Prevention of Hepatitis B reactivation in the setting of ...

<https://pubmed.ncbi.nlm.nih.gov/27291888>

Individuals with chronic hepatitis B (CHB) and previously infected but serologically cleared HBV infection are both susceptible to HBV reactivation. HBV reactivation in the setting of immunosuppression is a...

Cited by: 75 Author: Venessa Pattullo  
Publish Year: 2016

### Prevention of Hepatitis B Reactivation During ...

<https://www.hepatitis.va.gov/hbv/reactivation-prevention.asp>



Refer to Table 1: **Immunosuppresant Medications** by Class to determine which class of immunosuppressant the patient is planned to receive.

See more on [hepatitis.va.gov](http://hepatitis.va.gov)

### Hepatitis B reactivation in the setting of chemotherapy ...

<https://pubmed.ncbi.nlm.nih.gov/25954478>

Reactivation of HBV infection in the setting of chemotherapy and immunosuppression may lead to fulminant liver failure and death, but there is a cumulative body of evidence that these are potentially...

Cited by: 32 Author: Venessa Pattullo  
Publish Year: 2015

### Hepatitis B Reactivation During Immunosuppressive Therapy ...

<https://pubmed.ncbi.nlm.nih.gov/27257429>

Context: Due to the close relationship between the immune system and the hepatitis B virus (HBV)

## Hepatitis B

Medical Condition



A serious infection of the liver caused by hepatitis B virus (HBV).

- Common (More than 200,000 cases per year in US)
- Transmitted through direct contact
- Usually preventable by vaccine
- Often requires lab test or imaging
- Treatments can help manage condition, no known cure
- Can be lifelong

An infection caused by HBV that affects the liver. Spreading through exposure to virus by blood, semen, saliva, or vaginal fluids, the virus is transmitted through unsafe sexual practices and from an infected mother to her child. Symptoms include loss of appetite, nausea, body aches and fever progressing to jaundice. Chronic form of the infection is not curable, but HBV is preventable by vaccination.

### Symptoms